Rapidly advancing and proprietary oncology pipeline consisting of novel monoclonal antibodies, with commercial rights retained.
These programs represent significant commercial opportunities and address populations with unmet medical needs. The Company’s product candidates represent promising and differentiable new cancer therapies that combine the selectivity of tumor targeting antibodies with the potency of traditional cancer therapies:

• Vicinium™ Phase II for the treatment of bladder cancer
• VB6-845 for the treatment of solid tumors

Differentiable mechanism and antibody target.
Viventia’s Armed Antibody approach represents a significant evolution in the field of antibody technology that addresses key limitations associated with both unarmed and conjugated antibody approaches. The principal advantages of Viventia’s platform are:

• Small antibody fragments facilitate effective tumor penetration
• Payloads are attached to antibody fragments through recombinant engineering, providing stable conjugations and limiting non-specific toxicity
• Tumor-activated payloads are exceptionally potent and are designed to specifically activate within the cell and to remain inert outside the cell

Powerful proprietary platforms generating novel antibodies and new targets.
Viventia offers a comprehensive, integrated R&D engine, capable of identifying new targets and developing human antibodies against those targets.

• Proprietary target discovery platform successfully applied to identify over 12 novel oncology drug targets to date
• Human immune response used to generate highly specific antibody libraries using proprietary Fusogenics platform
• High content Fusogenic library screening combines target binding and functional outcome
• Currently focused in oncology, applicable to other therapeutic categories

Clinical programs target EpCAM, one of the most frequently and intensely expressed tumor-associated targets identified to date.

• Well-validated, known expression pattern, yet underdeveloped as a cell surface target
• Similar in therapeutic scope and expression profile to EGFR, but currently devoid of the same competitive pressures
• Market potential exceeds one million new incident cases annually

Clear patent coverage on compounds; strong overall intellectual property foundation.
Proven IP strategy for early capture of inventions through timely drafting, filing and prosecution. Patent areas include:

• Extensive patents covering Viventia’s products, including composition of matter and use patents (17 patents issued, 66 pending)
• Leading patent position in discovery processes, including human-human hybridoma creation for oncology, Fusogenic library creation and UnLock target identification
• Additional patents providing protection around innovations in product engineering, manufacturing and associated processes (two patents issues, 8 pending)

cGMP facility provides advantages of in-house production.
Viventia’s production facility is predicated on achieving product development control from bench to bedside and the realization of quality drug product for the purpose of meeting pre-clinical and clinical needs.

• Large production infrastructure, including process development, equipment, utilities and quality systems that allow a streamlined and flexible approach to production flowing rapidly from R&D to manufacturing
• Scalable production processes and capabilities facilitates advancement from the clinic through to the market
• Flexibility in production shortens development timelines and saves costs

Highly skilled employees led by an accomplished management team.
Executive management team has a strong track record of success focused on product development and achievement.